Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial

Adjuvant trastuzumab emtansine showed improved invasive disease-free survival compared with trastuzumab in HER2-positive early breast cancer.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2Sv50fN